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Visual function and long-term chloroquine treatment
P. R. BARTEL, P. ROUX, E. ROBINSON, I. F. ANDERSON, S. W. BRIGHTON,
H.]. VANDERHOVEN, P.J. BECKER
Abstract Ophthalmic eXaIIlinations and selected tests of
visual function were perfonned on 64 patients with
rheumatoid arthritis who had received daily doses
of 200 mg chloroquine sulphate for periods rang:..
iilg from 3 to 11 months. Visual fields were deter-
mined by Humphrey automated perimetry and
Amsler grids and a further battery of four tests of
macular function (visual evoked potentials, criti-
cal flicker fusion threshold, Cambridge contrast
sensitivity and the macular dazzle test) were
administered. No case of retinal pigmentary
abnonnalities plus visual loss was found, but 2
patients were advised to cease chloroquine
therapy on the basis of funduscopic findings. A
small group of patients with relatively poor scores
on one or more tests had normal visual fields and
ophthalmic findings. There were no significant
partial correlations between test results and the
cumulative dose of chloroquine. These results
support the opinion that currently recommended
doses of chloroquine pose a minimal risk of retinal
toxicity.
S Afr Med J 1994; 84: 32·34.
Deparnnents ofNeurology, Ophthahnology and Physical
Medicine and Rheumatology, University ofPretoria and
H. F. Verwoerd Hospital, Pretoria
P. R. BARTEL, PH.D.
E. ROBINSON, BA
P. ROUX:, M.B. CH.B., M.MED (OPHTH.), D.V.G., F.C.O. (Lo!--'TI).)
S. W. BRlGHTO J, M.B. CH.B., M.MED. (pHYs.,"IED.), M.D.
265 Beckett Street, Arcadia, Pretoria
1. F. MTDERSON, M.B. B.CH., M.RC.P., F.RC.P.
Suite 215, Pretoria Eye Institute, 630 Schoeman Street, Arcadia,
Pretoria
H. J. VAN DER HOVEN, M.B. CH.B., M.MED. (OPHTH.)
Institute for Biostatistics of the South African Medical Research
Council, Pretoria
P. J. BECKER, PHD.
Accepted 24 Mar 1993.
Chloroquine and its derivatives are being usedincreasingly in the treannent of connective tissuediseases. lOcular side-effects of prolonged
chloroquine use, especially corneal deposits, which are
generally associated with either no or only minor visual
symptoms, are common. Diplopia and defects in con-
vergence and accommodation may occasionally be
reponed. However, the risk of serious retinal disease
and visual deficits, even if these are very infrequent,2 is
of paramount imponance.
Various tests have been suggested as potential
markers of impending retinal dysfunction and their
application may pennit the withdrawal of chloroquine
before pennanem damage is caused.' While the.Amsler
grid has been advocated as an ideal screening test; some
other relatively easily administered tests have not been
evaluated thoroughly.
This study involved the screening of rheumatoid
arthritis patients for retinal toxicity by detailed ophthal-
mological examinations and assessment of visual fields
and colour vision. In addition, a battery of selected tests
of macular function was administered.
Patients and methods
Patiems with rheumatoid arthritis were referred by one
of twO physiciiillS. Si..xty-four patients who complied
with the physical requirements of the test battery were
entered into the study. All were receiving daily doses of
200 mg chloroquine sulphate, and most took additional
medication. The patients ranged in age from 12 to 73
years and there were 15 males and 49 females.
Clinical information regarding diagnosis, duration
and extent of disease, and medication was provided by
the referring physician.
A detailed ophthalmic examination was perfonned
on each patient according to protocol and the findings
were classified into five categories: refraction, eye moti-
lity, pupil reactions, slit-lamp microscopy and fundu-
scopy. Colour vision was assessed by the first 15 plates
Variable rt p
Mean latency of Pl00 -0,092 0,47
Maximum latency of P100 -0,106 0,40
Mean amplitude of PI 00 0,004 0,97
Minimum amplitude of Pl00 -0,017 0,89
Mean frequency -0,123 0,34
Minimum frequency -0,176 0,17
Mean contrast score -0,044 0,73
Minimum contrast score -0,106 0,41
Mean score -0,035 0,78
Maximum score -0,04 0,69
Discussion
Parients with relarively poor performance in the
VEP, critical flicker fusion and macular dazzle tests were
identified using a criterion of 2 or more standard devia-
tions above or below the group mean score for both
eyes, as appropriare. Owing to high variabiliry in the
contrast sensitiviry scores, an arbitrary cur-off of 100 or
less points bilaterally was used. These findings appear in
Table m. Within patienrs, relatively poor scores were
isolated and, furthermore, there was no association
berween these scores and the cumulative dose of chloro-
quine.
• The mean scores derived from scores for the right and left eyes tested separately
and the worst score (maximum or minimum as appropriate) for either eye were
considered.
t Partial correlation between the cumulative dose of chloroquine and test score
after correcting for age.
This study showed that retinal pigmenrary changes plus
visual field defects were not associated with chloroquine
toxiciry, a finding which is not surprising in view of the
relatively low doses involved.'
After commencement of this study it became appar-
enr thar red stimuli, and not white as we used, are opti-
mal in the Humphrey automated perimeter.4 However,
it is unlikely that field defecrs were missed, since the
Amsler grids appear to have a higher sensitiviry than
kinetic and static field testing"
The Amsler grids were bilaterally abnormal in 2
patienrs with normal ophthalmological findings and
unexceptional results on the other tests of visual func-












Partial correlation coefficients between the cumulative
dose of chloroquine and scores on various tests of
visual function.*
TABLE I.
Results of selected specialised tests of macular function
(mean ± SO)
Eye
Test Variable· tested Result
VEPs Latency of Right 97,6 ± 5,8
Pl00 (ms) Left 98,S ± 6,2
Amplitude of Right 5,6 ± 2,3
Pl00 (flV) Left 5,2 ± 2,2
Critical flicker Frequency (Hz) Right 26,S ± 3,5
fusion Left 27,2 ± 3,8
Cambridge Contrast score Right 208,6 ± 113,2
contrast Left 206,2 ± 105,0
sensitivity
Macular Score (s) Right 44,8 ± 36,5
dazzle Left 45,S ± 34,6
Results
of the Ishihara Colour Blindness Tesr. Visual fields were
derermined for each eye by means of a Humphrey auro-
mared perimerer, using the 10 - 2 whire programme,
and by Amsler grids.
A furrher battery of specialised laborarory resrs
included:
1. Parrern reversal visual evoked porentials (VEPs),
elicired by reversing a checkerboard parrern at a rare
of 1,9 stimuli per second on a television monitor with a
field size of 15° x 12° (individual squares subtended 28'
of arc). Monocular stimulation was used and the major
PI00 porential recorded from a mid-occipiral to a mid-
fronral electrode derivation was assessed.
2. Crirical flicker fusion frequency for each eye,
using an appararus consisring of red lighr emining
diodes seen through an artificial pupil in Maxwellian
view at oprical infiniry. Flicker threshold was deter-
mined by a compurer-based system using a combination
of the method of limits and a rwo-alremative forced-
choice strategy.
3. Contrast sensitiviry for each eye, by means of the
Cambridge Low Contrast Gratings.
4. Macular dazzle (phorostress), by directing the
lighr of a direct ophthalmoscope, from a disrance of
3 cm, through undilared pupils ar each macula for 10
seconds and recording the rime to rhe recovery of
preresr visual acuiry.
The clinical findings were coded for analysis. Test
resulrs were correlared with the duration of chloroquine
therapy after correcting for age.
The duration of therapy ar the time of resting ranged
from 3 to III months. The total cumularive dose of
chloroquine ranged from 18 to 671 g, with a group
mean of 136 g.
Eye motiliry and pupillary reactions were normal in
all parienrs. Findings on slir-Iamp microscopy of the
cornea, anrerior chamber, vitreous humour and iris were
normal in 95% of patients. Lens abnormalities consisr-
ing of cararacrs were present in 14%.
Findings on funduscopic examination of the maculae
were normal in 91 % of patients. In 2 patients pigmen-
tary changes suggestive of chloroquine toxiciry were
encountered; the cumulative chloroquine doses in these
cases were 90 and 126 g. These patienrs were advised
to stop chloroquine therapy. A further 3 patienrs had
macular changes unrelared to the clinical appearance of
chloroquine maculopathy - 2 had unilareral pigmen-
tary changes, and a further patienr had bilareral drusen
and a small haemorrhage in the righr fovea.
Visual acuiry was 6/12 or better in 97% of patienrs
and cataracts accounred for the reduced visual acuiry.
Colour vision was normal in 61 of 63 patients; 2 had
red-green colour blindness.
Visual fields as derermined on Amsler grids were
normal in 59 of 64 patients and the findings were unreli-
able in 1. A bilateral abnormaliry consisting of faded or
missing squares is regarded as particularly importanr for
assessing the side-effects of chloroquine4 and was detect-
ed in 2 patients; I of them had bilateral cararacts, while
the other had normal ophthalmic findings. Both patienrs
had normal results on Humphrey perimeter and colour
vision testing. A further 2 patienrs had unilateral Amsler
grid abnormalities.
The findings of the specialised tests of visual function
are summarised in Table I and the correlations between
resr performance and the duration of chloroquine




Findings in patients with relatively poor scores bilaterally on certain tests·









59 + + + 140
'Poor scores (+) on VEPs, critical flicker fusion threshold (CFFT), mac~lar dazzle (MD) and Cambridge contrast sensitivity (CCS) are indicated; + also indicates bilateral
Amsier grid (AG) abnormalities, and abnormalities on Humphrey automated perimetry (HAP) and Ishihara tests for colo"r blindness (11), and fundoscopic findings
suggestive of retinal chloroquine toxicity (FA). The cumulative dose of chloroquine (COG) (in grams) is given for each patient with relatively poor test scores. The group
mean cumulative chloroquine dose was 136 g.
cases were normal. The sensitivity of the Amsler grid
has been established, and its use in patients on long-
term chloroquine therapy is strongly advocated because
it is also inexpensive and can be self-administered by
the patient. 5 However, false-negative findings iIJ. the
presence of suggestive macular pigmentary changes and
central field defects have been reponed.·
The 2 patients with retinal pigmentary changes sug-
gestive of chloroquine toxicity had no signs of visual dis-
turbance apan from red-green colour blindness in 1
case. However, it was recommended by the ophthal-
mologist that chloroquine should be withdrawn as a
safety precaution.
The other specialised tests of visual functioning did
not conelate significantly with the duration of chloro-
quine therapy, and retinal findings in the 2 cases in
which these suggested chloroquine toxicity were un-
exceptional. The few patients with relatively poor test
scores tended to have isolated positive findings for one
test only and no ophthalmic and/or visual field abnor-
malities compatible with chloroquine toxicity. One
patient with markedly prolonged macular dazzle times
also had poor contrast sensitivity scores and a colour
vision deficit. However, the visual field, visual acuity
and findings on ophthalmic examination were normal.
The role of these tests in the routine assessment of
patients using chloroquine is questionable without fur-
ther evidence.
Apart from the various visual field tests, other spe-
cialised tests of visual function have not found a place in
the routine evaluation of patients for possible chloro-
quine toxicity. Contrast sensitivity has been reponed as
being superior to VEPs and to the electro-oculogram in
the detection of macular dysfunction. 7 These positive
findings occurred in patients with normal clinical results
and were not assessed relative to visual fields. False-pos-
itive results were also noted. In some cases contrast sen-
sitivity was markedly reduced in patients with normal
visual fields and normal ophthalmic findings.
The critical flicker fusion threshold has been advo-
cated as a potential predictor of retinal toxicity.s Our
patients with relatively low thresholds had normal visual
fields and ophthalmological findings. This also applied
to patients with unusually prolonged macular dazzle
times. It has been reponed that dazzle times are often
longer in patients taking chloroquine than in controls;
however, in patients with early chloroquine retinopathy
they were no longer than in patients without retino-
pathy!
Findings of reduced macular function in specialised
tests of vision, in the absence of positive visual field and
clinical results, do not at present seem to warrant dis-
continuation of chloroquine therapy. Even early, small,
relative scotomas are not necessarily regarded as abso-
lute indications for its cessation!
The results of this study are compatible with the
opinion that doses of chloroquine currently advocated
for patients with connective tissue disease pose a mini-
mal risk of retinal toxicity. A baseline ocular examina-
tion followed by annual examinations is regarded as suf-
ficient to detect reversible retinal disease before visual
loss.2 The inexpensive and easily self-administered
Amsler grid could be offered to patients as an additional
precaution. This test has been modified to improve its
reliability and sensitivity: and its self-administration
every 2 weeks has been strongly advocated! Another
group considers screening for retinal toxicity unneces-
sary when hydroxychloroquine is prescribed according
to body mass after a circumscribed baseline ophthalmic
examination. 10
REFERENCES
1. Scherbel A. Use of synthetic antimalarial drugs and other agents for
rheumatoid arthritis: historic and therapeutic perspective. Am ]
Ophtha/molI983; 75: 1-4.
2. Maksymowych W, Russell AS. Anrimalarials in theumatology: effi-
cacy and safery. Semin Arrhritis Rheum 1987; 16: 206-221.
3. Bemstein HN. Ophthalmologic considerations and testing in
patients receiving long-term anrimalarial therapy. Am ] Med 1983;
75: suppl, 25-34. .
4. Easterbrook M. Ocular effects and safety of antimalarial agents. Am
] Med 1988; 85: suppl4A, 23-29.
5. Easterbrook M. The use of Arnsler grids in early chloroquine
retinopathy. Ophthalmology 1984; 91: 1368-1372.
6. Percival SPB, Meanoch 1. Ophthalmological safery and clinical
assessment in rheumatoid arthritis. BM] 1968; 3: 579-584.
7. Bishara SA, Mararnoros N. Evaluation of several tests in screening
for chloroquine maculopathy. Eye 1989; 3: 777-782.
8. AI Khamis AR, Easterbrook M. Critical flicker fusion frequency in
early chloroquine retinopathy. Can] Ophtha/molI983; 18: 217-219.
9. Bernstein HN. Ocular safety of hydroxychloroquine. Ann
Ophchalmoll991; 23: 292-296.
10. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV.
Screening for hydroxychloroquine retinal toxiciry: is it necessary?
Eye 1990; 4: 572-576.
